Tagged Articles

dapagliflozin 21 articles

Some diabetes meds linked to increased risk for serious kidney injury

A growing number of cases of acute kidney injury in patients taking one of the type 2 diabetes medications canagliflozin (Invokana, Invokamet) or dapagliflozin (Farxiga, Xigudo XR) have prompted the Food and Drug Administration (FDA) to strengthen the current warnings on the drugs. Canagliflozin and dapagliflozin are in a class of type 2 diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. They are used along with diet and exercise to lower blood sugar levels in adults with type 2 diabetes. The drugs work by causing the kidneys to remove sugar from the body and excrete it through the urine. ... Read More

FDA strengthens boxed warning for diabetes drug Xigduo XR

The Food and Drug Administration (FDA) has approved safety label changes for the type 2 diabetes drug Xigduo XR that give more extensive updates to the boxed warning involving the risk for lactic acidosis. Lactic acidosis is a medical condition characterized by the buildup of lactate in the body. Lactic acidosis in patients taking Xigduo have reportedly resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. “The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain,” the updated warning states. Xigduo is a combination of the medications ... Read More

Type 1 diabetics treated with Farxiga at risk for ketoacidosis

The type 2 diabetes drugs Farxiga and Victoza, when used together, are an effective treatment for managing blood sugar levels in patients with type 1 diabetes, but patients were at an increased risk of developing ketoacidosis, a serious condition in which too much acid builds up in the blood. The findings were noted by researchers with the State University of New York in Buffalo, who tested 30 patients already taking insulin and Victoza, known chemically as liraglutide, and randomly gave them either Farxiga, known chemically as dapagliflozin, or a placebo as an add-on for 12 weeks. HbA1c levels fell by ... Read More

FDA warns of serious urinary tract infections, ketoacidosis with SGLT2 diabetes drugs

New warnings have been added to the safety labels of some type 2 diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors about side effects of too much acid in the blood and serious urinary tract infections, both of which may require hospitalization, the Food and Drug Administration (FDA) announced in a Safety Alert. In May 2015, the FDA launched an investigation into the risk of ketoacidosis with SGLT2 inhibitors after a review of the agency’s adverse event data revealed 73 cases of ketoacidosis from March 2013 to May 2015 in patients with type 1 or type 2 diabetes treated with ... Read More

Diabetes drugs including Invokana linked to ketoacidosis

Three type 2 diabetes drugs have been linked to ketoacidosis, a serious metabolic state that can lead to diabetic coma or even death, the Food and Drug Administration (FDA) warned. The drugs include the brand names Invokana (canagliflozin), Farxiga (dapagliflozin) and Jardiance (empagliflozin), which all belong to a class called sodium-glucose co-transporter-2 (SGLT2) inhibitors. At least two studies have found an increased risk of ketoacidosis, or diabetic ketoacidosis (DKA), in patients who take an SGLT2 inhibitor. The warning is based on a search of reports of ketoacidosis reported to the FDA Adverse Event Reporting System, which revealed 20 cases of ... Read More

FDA approves new type 2 diabetes treatment

The Food and Drug Administration (FDA) has approved Xigduo, a new once-daily treatment for type 2 diabetes. Xigduo is a combination of an extended release version of the long-used diabetes drug metformin and dapagliflozin, a diabetes drug recently approved by the FDA and marketed under the name Farxiga. Xigduo is the first and only once-daily combination oral medication of an SGLT2 inhibitor and an extended release version of metformin to be approved in the United States. The drug is intended to be used in combination with exercise and diet to improve glycemic control in adults with type 2 diabetes. The ... Read More

Combining old diabetes drug with new improves blood sugar control

Combining the commonly used metformin with another class of medication can greatly improve blood sugar control in Type 2 diabetics, according to new research. Metformin is in a class of drugs called biguanides. It works by decreasing the amount of glucose absorbed by food and the amount of glucose made by the liver. By doing this, it increases the body’s response to insulin. It is used alone or with other medications, including insulin, to treat type 2 diabetes. The new study, funded by drug maker Sanofi Aventis, tested metformin in combination with a drug in a new class of type ... Read More

FDA orders post-market studies on newly approved type 2 diabetes drug Jardiance

Jardiance (empagliflozin), a new type 2 diabetes drug, has been granted approval by the U.S. Food and Drug Administration (FDA). The medication can be used alone or added to existing treatment regimens to control blood sugar levels. Jardiance, made by Boehringer Ingelheim, is in a class of drugs called sodium glucose co-transporter 2 (SGLT2) inhibitors. These drugs work by stopping blood sugar from becoming reabsorbed by the kidneys. Thus, more glucose is excreted by the kidneys, which lowers blood sugar levels. Other SGLT2 drugs include Invokana (canagliflozin) and Farxiga (dapagliflozin). The FDA approved Jardiance based on a review of seven ... Read More

European drug regulators approve new type 2 diabetes treatment

European drug regulators have approved Eli Lilly and Boehringer Ingelheim’s new Type 2 diabetes drug epagliflozin, which will be marketed under the brand name Jardiance. The once-daily tablet is designed to reduce blood sugar levels by blocking glucose reabsorption in the kidneys and remove excess glucose through the urine. Unlike other diabetes treatments, Jardiance does not rely on a patient’s insulin levels in order to be effective. Jardiance is in a class of Type 2 diabetes drugs known as sodium glucose co-transporter 2 (SGLT-2) inhibitors. Other drugs in this class include Canagliflozin, which was the first in the class to ... Read More

Japan approves new type 2 diabetes drug dapagliflozin

Japanese drug authorities have approved Forxiga (dapagliflozin) for the treatment of type 2 diabetes. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is a once-daily oral treatment that works independent of insulin to help remove excess glucose from the body. It is currently approved in more than 40 countries around the world, including the United States, where it is marketed under the brand name Farxiga. SGLT-2 inhibitors are a relatively new class of diabetes medications. It was the first of its kind to be approved in Europe, and the second, behind Johnson & Johnson’s Invokana, in the United States. The class ... Read More